Neutrophil Phenotypic Profiling and Organ Injury Assessment in Patients With Sepsis
Part of paid clinical trials in Boston, Massachusetts.
- Sponsor
- Boston Children's Hospital
- Study ID
- NCT04103268
- Status
- Recruiting
Conditions
- Sepsis
Eligibility Criteria
- Sex
- ALL
- Age
- 1 Month - 17 Years
- Healthy Volunteers
- Not accepted
Interventions
- sepsis — OTHERpatients in the ICU with infection called sepsis
Study Details
In this research study we want to learn more about the character of neutrophils that are present in the blood of children with sepsis. Sepsis is a severe type of infection, affecting various parts of the body. Neutrophils are a type of white blood cell that are part of the body's immune system. Even though neutrophils are important in getting rid of germs, they also may be harmful to parts of the body by causing injury in organs in patients with sepsis. Neutrophils can change their character in sepsis. Because of this, it is important for doctors to know what kind of neutrophils are in the blood of children with sepsis so that they can work to develop therapies to prevent these cells from being harmful.
Key Dates
- Start date
- Aug 4, 2020
- Status verified
- Jan 2026
- Primary completion
- Sep 30, 2026
- Completion
- Dec 1, 2026
Study Design
- Enrollment
- 72 participants (estimated)
Arms
- Arm: Sepsis
- Arm: Control
Primary Outcome Measure
neutrophil populations [ Time Frame: up to 1 month ]
Central Contacts
- Koichi Yuki, MD617-355-6225
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Boston Children's Hospital | Boston | Massachusetts | 02115 |
Find similar trials in Boston, MA
Related Studies
- Biomarkers in InfectionRecruiting · Beth Israel Deaconess Medical Center · Boston, Massachusetts
- Expression Profiles of Integrin αDβ2 on Neutrophils in SepsisRecruiting · Boston Children's Hospital · Boston, Massachusetts
- Pre-hospital Ventilation Clinical StudyEnrolling By Invitation · Zoll Medical Corporation · Baton Rouge, Louisiana
- A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.PHASE2 · Recruiting · AstraZeneca · Tucson, Arizona